39 related articles for article (PubMed ID: 2528460)
1. Bispecific F (ab')2 monomer prepared with anti-CD3 and anti-tumor monoclonal antibodies is most potent in induction of cytolysis of human T cells.
Nitta T; Yagita H; Azuma T; Sato K; Okumura K
Eur J Immunol; 1989 Aug; 19(8):1437-41. PubMed ID: 2528460
[TBL] [Abstract][Full Text] [Related]
2. Preparation and activity of conjugate of monoclonal antibody HAb18 against hepatoma F(ab')(2) fragment and staphylococcal enterotoxin A.
Yang LJ; Sui YF; Chen ZN
World J Gastroenterol; 2001 Apr; 7(2):216-21. PubMed ID: 11819763
[TBL] [Abstract][Full Text] [Related]
3. Rapid and potent induction of cell death and loss of NK cell cytotoxicity against oral tumors by F(ab')2 fragment of anti-CD16 antibody.
Jewett A; Teruel A; Romero M; Head C; Cacalano N
Cancer Immunol Immunother; 2008 Jul; 57(7):1053-66. PubMed ID: 18188563
[TBL] [Abstract][Full Text] [Related]
4. Development of a bispecific F(ab')2 conjugate against the complement receptor CR3 of macrophages and a variant CD44 antigen of rat pancreatic adenocarcinoma for redirecting macrophage-mediated tumor cytotoxicity.
Somasundaram C; Arch R; Matzku S; Zöller M
Cancer Immunol Immunother; 1996 Jul; 42(6):343-50. PubMed ID: 8830737
[TBL] [Abstract][Full Text] [Related]
5. Bispecific-Ab-based immunoassay of thyroid-stimulating hormone.
Inouye K
Cancer Immunol Immunother; 1997; 45(3-4):159-61. PubMed ID: 9435863
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution and plasma survival in mice of anti-melanoma monoclonal antibody cross-linked to OKT3.
Winkler MA; Price JO; Foglesong PD; West WH
Cancer Immunol Immunother; 1990; 31(5):278-84. PubMed ID: 2142894
[TBL] [Abstract][Full Text] [Related]
7. Preparation and analysis of bifunctional immunoconjugates containing monoclonal antibodies OKT3 and BABR1.
Foglesong PD; Winkler MA; Price JO; Marshall GD; Reagh SH; Bush DA; Hixson KS; West WH
Cancer Immunol Immunother; 1989; 30(3):177-84. PubMed ID: 2598187
[TBL] [Abstract][Full Text] [Related]
8. Structural design of tetravalent T-cell engaging bispecific antibodies: improve developability by engineering disulfide bonds.
Yu L; Huang N; Ge L; Sun H; Fu Y; Liu C; Wang J
J Biol Eng; 2021 Jun; 15(1):18. PubMed ID: 34187511
[TBL] [Abstract][Full Text] [Related]
9. Flow cytometric analysis of sialyl Lewis A antigen on human cancer cells by using F(ab')2μ fragments prepared from a mouse IgM monoclonal antibody.
Morimoto K; Inouye K
Cytotechnology; 1997 Sep; 24(3):219-26. PubMed ID: 22358765
[TBL] [Abstract][Full Text] [Related]
10. Self-assembled antibody multimers through peptide nucleic acid conjugation.
Kazane SA; Axup JY; Kim CH; Ciobanu M; Wold ED; Barluenga S; Hutchins BA; Schultz PG; Winssinger N; Smider VV
J Am Chem Soc; 2013 Jan; 135(1):340-6. PubMed ID: 23210862
[TBL] [Abstract][Full Text] [Related]
11. Facile Generation of Potent Bispecific Fab via Sortase A and Click Chemistry for Cancer Immunotherapy.
Bai X; Liu W; Jin S; Zhao W; Xu Y; Zhou Z; Chen S; Pan L
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572769
[TBL] [Abstract][Full Text] [Related]
12. Antibody Therapies for Acute Myeloid Leukemia: Unconjugated, Toxin-Conjugated, Radio-Conjugated and Multivalent Formats.
Williams BA; Law A; Hunyadkurti J; Desilets S; Leyton JV; Keating A
J Clin Med; 2019 Aug; 8(8):. PubMed ID: 31434267
[TBL] [Abstract][Full Text] [Related]
13. Development of a bioassay to detect T-cell-activating impurities for T-cell-dependent bispecific antibodies.
Lee HY; Contreras E; Register AC; Wu Q; Abadie K; Garcia K; Wong PY; Jiang G
Sci Rep; 2019 Mar; 9(1):3900. PubMed ID: 30846832
[TBL] [Abstract][Full Text] [Related]
14. Bispecific antibodies and CARs: generalized immunotherapeutics harnessing T cell redirection.
Zhukovsky EA; Morse RJ; Maus MV
Curr Opin Immunol; 2016 Jun; 40():24-35. PubMed ID: 26963133
[TBL] [Abstract][Full Text] [Related]
15. Months and days fly like arrows.
Sato K
Childs Nerv Syst; 1996 Aug; 12(8):429-33. PubMed ID: 8891360
[No Abstract] [Full Text] [Related]
16. Fas and its ligand in a general mechanism of T-cell-mediated cytotoxicity.
Hanabuchi S; Koyanagi M; Kawasaki A; Shinohara N; Matsuzawa A; Nishimura Y; Kobayashi Y; Yonehara S; Yagita H; Okumura K
Proc Natl Acad Sci U S A; 1994 May; 91(11):4930-4. PubMed ID: 7515183
[TBL] [Abstract][Full Text] [Related]
17. A new form of specific targeting cancer immunotherapy using anti-tumor monoclonal antibody-conjugated lymphokine-activated killer cells.
Shiraiwa H; Sekine T; Tobisu K; Kakizoe T; Koiso K
Jpn J Cancer Res; 1991 Jun; 82(6):621-3. PubMed ID: 1906847
[TBL] [Abstract][Full Text] [Related]
18. CD4 and CD8 regulate interleukin 2 responses of T cells.
Takahashi K; Nakata M; Tanaka T; Adachi H; Nakauchi H; Yagita H; Okumura K
Proc Natl Acad Sci U S A; 1992 Jun; 89(12):5557-61. PubMed ID: 1608966
[TBL] [Abstract][Full Text] [Related]
19. In vitro anti-tumor activity of anti-c-erbB-2 x anti-CD3 epsilon bifunctional monoclonal antibody.
Sugiyama Y; Aihara M; Shibamori M; Deguchi K; Imagawa K; Kikuchi M; Momota H; Azuma T; Okada H; Alper O
Jpn J Cancer Res; 1992 Jun; 83(6):563-7. PubMed ID: 1353752
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
